- Home
- BV vs RCUS Comparison
BV vs RCUS Comparison
Compare BV & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BV
- RCUS
- Stock Information
- Founded
- BV 1939
- RCUS 2015
- Country
- BV United States
- RCUS United States
- Employees
- BV N/A
- RCUS N/A
- Industry
- BV Business Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- BV Consumer Discretionary
- RCUS Health Care
- Exchange
- BV Nasdaq
- RCUS Nasdaq
- Market Cap
- BV 1.6B
- RCUS 1.4B
- IPO Year
- BV 2018
- RCUS 2018
- Fundamental
- Price
- BV $15.95
- RCUS $15.52
- Analyst Decision
- BV Buy
- RCUS Buy
- Analyst Count
- BV 8
- RCUS 12
- Target Price
- BV $17.41
- RCUS $34.50
- AVG Volume (30 Days)
- BV 506.0K
- RCUS 755.7K
- Earning Date
- BV 01-29-2025
- RCUS 11-06-2024
- Dividend Yield
- BV N/A
- RCUS N/A
- EPS Growth
- BV N/A
- RCUS N/A
- EPS
- BV 0.20
- RCUS N/A
- Revenue
- BV $2,767,100,000.00
- RCUS $263,000,000.00
- Revenue This Year
- BV $3.86
- RCUS $127.13
- Revenue Next Year
- BV $3.55
- RCUS N/A
- P/E Ratio
- BV $79.90
- RCUS N/A
- Revenue Growth
- BV N/A
- RCUS 119.17
- 52 Week Low
- BV $7.75
- RCUS $13.52
- 52 Week High
- BV $18.89
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- BV 39.55
- RCUS 44.11
- Support Level
- BV $16.51
- RCUS $14.78
- Resistance Level
- BV $17.16
- RCUS $18.07
- Average True Range (ATR)
- BV 0.60
- RCUS 0.96
- MACD
- BV -0.16
- RCUS -0.16
- Stochastic Oscillator
- BV 19.43
- RCUS 22.32
About BV BrightView Holdings Inc.
BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature, and the Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.